Previous Close | 24.78 |
Open | 24.85 |
Bid | 26.52 x 1800 |
Ask | 28.00 x 800 |
Day's Range | 24.68 - 27.02 |
52 Week Range | 13.11 - 42.16 |
Volume | |
Avg. Volume | 1,489,013 |
Market Cap | 1.905B |
Beta (5Y Monthly) | 1.94 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.01 |
Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 76.57 |
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...
-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date -- SAN CARLOS, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the presentation of safety results from the ongoing Phase I clinical study of CCX559, the Company’s highly potent, orally administered PD-L1 checkpoint